SkinKandy.

SKINKANDY LIMITED

ABN 80 636 484 814

ASX RELEASE

19 November 2026

2026 Annual General Meeting Presentation

SkinKandy Limited ("**SkinKandy**", ASX: **SK1**) attaches the AGM Presentation to be delivered at the 2026 Annual General Meeting, scheduled for 10.00am (Sydney time) today.

Included in the AGM Presentation is a trading update, which is market sensitive.

This announcement has been authorised for release by the Board of SkinKandy Limited.

Investor enquiries
Carl Larzabal, Chief Financial Officer and Company Co-Secretary
investors@skinkandy.com

About SkinKandy
SkinKandy is Australia's and New Zealand's leading piercing specialist, dedicated to creating the world's most trusted piercing brand. Every customer experience is built on expert, certified piercers, uncompromising safety standards and premium body-safe jewellery.

SkinKandy.

ANNUAL GENERAL MEETING 2026

THURSDAY 19 NOVEMBER 2026



Board and attendees



Trent Peterson
Independent Non-Executive Chair



Dain Friis
Chief Executive Officer and Executive Director



Melanie Wilson
Independent Non-Executive Director; Chair, Audit and Risk Committee



Renee Jones
Independent Non-Executive Director



Mark Oliphant
Non-Executive Director and Founder; Chair, People and Remuneration Committee



Richard Whiteoak
Non-Executive Director

ALSO ATTENDING



Carl Larzabal
Chief Financial Officer and Company Co-Secretary



Eryl Baron
Company Co-Secretary, MUFG Corporate Markets



Patrice Scott
Auditor, KPMG

Graham Butcher
Returning Officer, MUFG Corporate Markets

Questions and voting

Questions

- Shareholders, proxies, attorneys and corporate representatives may ask questions when invited by the Chair
- Raise your voting card and wait for a microphone
- State your name and whether you are a shareholder or proxy
- Please direct questions to the Chair and keep them brief and relevant to the item under discussion
- Questions lodged before the meeting will also be addressed

Voting

- Voting on every item is by poll
- One vote for every fully paid ordinary share held, subject to the voting exclusions in the Notice of Meeting
- The poll is now open on all items; complete your voting card at any time
- Voting closes 5 minutes after the close of the meeting
- Results will be released to the ASX once votes are counted

Trent Peterson · Independent Non-Executive Chair

CHAIR'S ADDRESS



CEO'S ADDRESS · DAIN FRIIS

FY26 results

A strong first year as a listed company: ahead of Prospectus forecast on every key measure

Revenue
$90.2m
Up 29%; 2% ahead of forecast

LFL growth
9.6%
Prospectus forecast 8.1%

EBITDA
$24.6m
Up 41%

NPAT
$9.0m
Up 41%; 5% ahead of forecast

Studios
109
22 opened; one ahead of forecast

Cash conversion
101%
FY25: 92%

Cash reserves
$13.8m
No drawn debt

SK Certified piercers
>770
Up 22%; 1.1m KandyClub members

Pro forma results for the 52 weeks ended 4 July 2026, as presented in the FY26 results presentation (25 August 2026). Statutory revenue $90.5 million; statutory NPAT $0.6 million after $11.1 million of Offer costs expensed. The reconciliation of statutory to pro forma results is set out in the 2026 Annual Report. Cash reserves comprise cash and term deposits.

Growth strategy update

Strategy unchanged from the Prospectus. All three growth drivers are delivering in FY27.

1 ON TRACK

Expand the network across Australia and New Zealand

What we said: build towards 180 to 210 studios, with disciplined site selection.

UPDATES

- Opened 9 new studios in FY27 to date, including Merrylands opening on the AGM date, taking the network to 118, with 10 to 12 openings expected for the first half
- Above 850 SK Certified piercers at the AGM date, each one strengthening our moat

2 ON TRACK

Improve studio unit economics and grow online

What we said: maturing studios, premium jewellery and aftercare, more repeat visits.

UPDATES

- Gross margin remains strong and consistent with FY26; offers are value-led, not seasonal discounting
- Legendary Leaders Academy building our next studio and international leaders; senior team strengthened with GM Retail and GM Technology and Transformation roles
- Enhanced piercing training program and skillset recognition launched in Q1, lifting piercing standards across the network

3 ON TRACK

Enter other international markets

What we said: prove the model in one new market before committing to scale.

UPDATES

- South Africa progressing well as our potential first market beyond ANZ; the United Kingdom and United States remain priority markets
- Experienced retail executive in place as Country Manager
- Working towards first studios in H2 FY27, with a number of leases in negotiation

All figures at 14 November 2026 unless stated. New Zealand is considered the Group's first international market.

SkinKandy.

International expansion: phased plan and progress

Phasing unchanged. South Africa well progressed as our potential first market beyond ANZ, working towards first studios in H2 FY27.

PHASE 1

ANZ home market

- Network of 118 studios at the AGM date, targeting 180 to 210 at maturity
- Above 850 SK Certified piercers at the AGM date, with future leaders coming through our Legendary Leaders Academy
- Systems and support office built for multi-market operation

Status: delivering – 118 studios and growing

PHASE 2

First market beyond ANZ

MILESTONE TRACKER

☑	Market selection framework applied (whitespace, centre structure, regulatory pathway): South Africa well progressed	**Complete**
☑	Experienced retail Country Manager in place	**Complete**
☑	On-the-ground leasing and studio build partners engaged	**Complete**
☑	Multiple sites in negotiation	**In progress**
☐	First studios open	**Target H2 FY27**

Status: on track – first studios targeted for H2 FY27

PHASE 3

Multi-market roll-out

- Market-entry playbook proven in South Africa first, then applied to further markets – the United Kingdom and United States remain our other priority markets
- Further markets assessed with the same framework, sequenced on unit economics, sites and organisational capacity
- Growth layered onto the ANZ base, with capital committed in a disciplined way

Status: planned – FY28 and beyond

Note: Follows the phasing framework set out in the Prospectus (Figure 24), updated for progress to 14 November 2026.

Trade update and outlook

Strong momentum maintained, with revenue up 21% in the first 19 weeks of FY27 (to 14 November 2026).

FY27 outlook statements	Status	First 19 weeks of FY27 (to 14 November 2026) and outlook
Revenue growth expected to continue, supported by the roll-out and maturation of the existing network.	✓	First 19 weeks of FY27, revenue +21% vs PCP, maintaining the strong momentum reported in August. *Studios opened since the IPO are trading in line with expectations.*
ANZ studio roll-out of 18 to 20 new studios, plus refurbishments, relocations and upsizes.	✓	9 new studios opened in FY27 to date, including Merrylands opening on the AGM date (118 total), with 10 to 12 openings expected for the first half and a strong pipeline building. *Anticipating 18 to 20 new studios in FY27, excluding new international studios, plus 5–7 refurbishments, relocations and upsizes.*
Gross margin broadly consistent with FY26.	✓	Remains strong and consistent with FY26 across the first 19 weeks. *Margin stability is carefully managed — discounts are value-led rather than seasonal or cyclical.*
Existing-studio maturation — margin expansion supported by a large group of maturing studios.	✓	*Studios opened in FY26 growing well and tracking in line with expectations.*
International — initial investment and studio openings in FY27, with a modest negative near-term earnings contribution.	✓	South Africa well progressed as our potential first market beyond ANZ, with an experienced retail executive in place as Country Manager and multiple sites in negotiation. *Management working towards first studios opened in H2 FY27.*

Note: FY27 trading results are unaudited, for the 19 weeks to 14 November 2026.

Notice of Meeting

Dated 16 October 2026 · Returning Officer: Graham Butcher, MUFG Corporate Markets

Item 1	**Annual Financial Report**	No vote
Resolution 1	**Adoption of Remuneration Report**	Advisory
Resolution 2	**Election of Trent Peterson**	Ordinary
Resolution 3	**Election of Dain Friis**	Ordinary
Resolution 4	**Election of Renee Jones**	Ordinary
Resolution 5	**Re-election of Mark Oliphant**	Ordinary
Resolution 6	**Election of Melanie Wilson**	Ordinary
Resolution 7	**Re-election of Richard Whiteoak**	Ordinary
Resolution 8	**Approval of LTI grant of Performance Rights to Dain Friis**	Ordinary
Resolution 9	**Appointment of KPMG as auditor**	Ordinary

NO VOTE

Item 1 – Annual Financial Report

To receive and consider the Financial Report of the Company and its controlled entities, and the reports of the Directors and auditor, for the period ended 4 July 2026.

- The reports form part of the 2026 Annual Report, available on our investor relations website
- There is no vote on this item
- Questions on the management of the Company and the Financial Report, followed by questions for the auditor, KPMG

ADVISORY RESOLUTION

Resolution 1 – Adoption of Remuneration Report

ORDINARY RESOLUTION

"That the Remuneration Report for the period ended 4 July 2026 be adopted."

- The Remuneration Report is set out on pages 29 to 49 of the 2026 Annual Report
- The vote is advisory only and does not bind the Directors or the Company
- A voting exclusion applies to key management personnel named in the Remuneration Report and their closely related parties

The Directors unanimously recommend voting in favour

Proxy results – Resolution 1

Adoption of Remuneration Report

	For	Open[1]	Against	Abstain	Total
Votes (Shares)	90,187,173	2,199	10,000	609,286	90,199,372
% of votes cast	99.99%	0.00%	0.01%	–	100%

Proxy and direct votes lodged before the meeting, per MUFG Corporate Markets (proxy snapshot at 18 November 2026, 7.54am; 21 valid proxies lodged). 1. Open proxies held by the Chair will be voted in favour, where expressly authorised on the Voting Form (voting exclusion applies). Abstentions are not counted in the votes cast. Final results will be released to the ASX once the poll has closed.

ORDINARY RESOLUTIONS

Resolutions 2 to 7 – Election and re-election of Directors

Each an ordinary resolution, voted on separately · Profiles in the Notice of Meeting

RESOLUTION 2



ELECTION

Trent Peterson

Independent Non-Executive Chair

RESOLUTION 3



ELECTION

Dain Friis

Chief Executive Officer and Executive Director

RESOLUTION 4



ELECTION

Renee Jones

Independent Non-Executive Director

RESOLUTION 5



RE-ELECTION

Mark Oliphant

Non-Executive Director and Founder

RESOLUTION 6



ELECTION

Melanie Wilson

Independent Non-Executive Director

RESOLUTION 7



RE-ELECTION

Richard Whiteoak

Non-Executive Director

For each resolution, the Directors (other than the Director concerned) unanimously recommend voting in favour

Proxy results – Resolutions 2 to 7

Percentage of votes cast

Resolution	For	Open[1]	Against	Abstain (Shares)
2 – Election of Trent Peterson	91.58%	0.00%	8.42%	2,000
3 – Election of Dain Friis	100.00%	0.00%	0.00%	2,000
4 – Election of Renee Jones	100.00%	0.00%	0.00%	2,000
5 – Re-election of Mark Oliphant	100.00%	0.00%	0.00%	2,000
6 – Election of Melanie Wilson	100.00%	0.00%	0.00%	2,000
7 – Re-election of Richard Whiteoak	100.00%	0.00%	0.00%	0

Proxy and direct votes lodged before the meeting, per MUFG Corporate Markets (proxy snapshot at 18 November 2026, 7.54am; 21 valid proxies lodged). 1. Open proxies held by the Chair will be voted in favour. Abstentions are not counted in the votes cast. Final results will be released to the ASX once the poll has closed.

ORDINARY RESOLUTION · ASX LISTING RULE 10.14

Resolution 8 – LTI grant of Performance Rights to Dain Friis

ORDINARY RESOLUTION

"That approval be given for all purposes, including ASX Listing Rule 10.14, for the grant of Performance Rights to Dain Friis under the Company's Long Term Incentive Plan as his annual long-term incentive for the FY2027 financial year on the terms described in the explanatory notes accompanying this Notice of Meeting."

- Face value $696,000 (120% of FY2027 total fixed remuneration): 249,337 Performance Rights at a 5-day VWAP of $2.7914, granted for nil consideration
- Vesting: EPS growth (70%) and LFL sales growth (30%), measured over a 3-year performance period
- A voting exclusion applies to Dain Friis, his associates and other excluded persons

The Directors, other than Dain, unanimously recommend voting in favour

Proxy results – Resolution 8

LTI grant of Performance Rights to Dain Friis

	For	Open[1]	Against	Abstain	Total
Votes (Shares)	90,338,209	2,199	0	609,286	90,340,408
% of votes cast	100.00%	0.00%	0.00%	–	100%

Proxy and direct votes lodged before the meeting, per MUFG Corporate Markets (proxy snapshot at 18 November 2026, 7.54am; 21 valid proxies lodged). 1. Open proxies held by the Chair will be voted in favour, where expressly authorised on the Voting Form (voting exclusion applies). Abstentions are not counted in the votes cast. Final results will be released to the ASX once the poll has closed.

ORDINARY RESOLUTION

Resolution 9 – Appointment of KPMG as auditor

ORDINARY RESOLUTION

"That in accordance with section 327B(1)(b) of the Corporations Act 2001 and for all other purposes, KPMG, having been nominated by a shareholder and consented in writing to acting in the capacity of auditor, be appointed as the auditor of SkinKandy Limited."

- KPMG has been the auditor of the SkinKandy Group since 2023
- The Company is required to appoint an auditor at its first Annual General Meeting
- The shareholder nomination is in Attachment A to the Notice of Meeting

The Directors unanimously recommend voting in favour

Proxy results – Resolution 9

Appointment of KPMG as auditor

	For	Open[1]	Against	Abstain	Total
Votes (Shares)	94,564,644	833	1,366	2,000	94,566,843
% of votes cast	100.00%	0.00%	0.00%	–	100%

Proxy and direct votes lodged before the meeting, per MUFG Corporate Markets (proxy snapshot at 18 November 2026, 7.54am; 21 valid proxies lodged). 1. Open proxies held by the Chair will be voted in favour. Abstentions are not counted in the votes cast. Final results will be released to the ASX once the poll has closed.

THANK YOU

Please hand your completed voting card to the MUFG Corporate Markets team. The poll closes 5 minutes after the close of the meeting. Please join the Directors and senior executives for light refreshments.



Disclaimer

Important information

This presentation has been prepared by SkinKandy Limited (ABN 80 636 484 814) (Company) to provide summary information about the Company and its associated entities. The information in this presentation remains subject to change without notice. Except as required by law, the Company has no obligation to update or correct this presentation. This presentation is not a prospectus or other form of disclosure document under the Corporations Act 2001 (Cth) (Corporations Act) and does not contain all the information which would be required to be disclosed in a prospectus or other disclosure document. The information presented in this presentation may differ materially from that presented in any disclosure document prepared in connection with any offer of securities. The information contained in this presentation is for information purposes only. The information contained in this presentation is of general background and does not purport to be complete. It should be read together with the Company's other periodic and continuous disclosures lodged with the Australian Securities Exchange, which are available at www.asx.com.au. The information contained in this presentation does not constitute investment or financial product advice (or taxation or legal advice) and is not intended to be used as the basis for making an investment decision. In providing this presentation, the Company has not considered the objectives, financial position or needs of any particular person.

No liability

No representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information contained in this presentation. To the fullest extent permitted by law, none of the Company, its related bodies corporate (as defined in the Corporations Act), shareholders or affiliates, or any of its or their respective officers, directors, employees, affiliates, partners, representatives, consultants, agents or advisers guarantees or makes any representations or warranties, express or implied, as to or takes responsibility for loss arising from reliance on the information contained in this presentation. You must consider your own financial situation, objectives and needs and conduct your own independent investigations, assessments and enquiries, including obtaining investment, legal, tax, accounting and other such advice necessary or appropriate.

Future performance

This presentation may contain certain forward looking statements, forecasts, estimates, projections and comments about future events, including the Company's beliefs, assumptions and expectations about the performance of its business, its strategies and market trends. Forward looking statements can generally be identified by the use of forward looking words such as, "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "goals", "aims", "target", "outlook" and other similar expressions. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements. Forward-looking statements may also be made, verbally or in writing, by the Company's board or management in connection with this presentation. Such statements are subject to the same limitations, uncertainties, assumptions and disclaimers set out in this presentation. Forward-looking statements that reference past trends or activities should not be taken as a representation that such trends or activities will necessarily continue in the future. Forward looking statements involve inherent risks and uncertainties, both general and specific, and there is a risk that such predictions, forecasts, projections and other forward looking statements will not be achieved. Any forward looking statements are provided as a general guide only, and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainty and other factors, many of which are outside the control of the Company. Past performance is not necessarily a guide to future performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of any forward looking statements, forecast financial information or other forecast. Forward looking statements reflect expectations based on information known as at the date of this presentation.

Financial and other data

Non-IFRS financial information is financial information that is presented other than in accordance with relevant accounting standards and may not be directly comparable with similarly titled measures used by other companies. Non-IFRS financial measures are used internally by management to assess the performance of the business and make decisions on the allocation of resources, and are included in this presentation to provide greater understanding of the underlying financial performance of the Company's operations.

This presentation contains certain non-IFRS financial information, including pro forma revenue, pro forma EBITDA, pro forma NPAT, cash conversion and like-for-like (LFL) revenue growth. FY26 results are presented on a pro forma basis, consistent with the Prospectus dated 12 May 2026. Reconciliations of statutory to pro forma results are set out in the Company's Annual Report for the 52-week period ended 4 July 2026 and in Section 14.3 of the FY26 Appendix 4E.

The trading update for the first 19 weeks of FY27 (to 14 November 2026) is based on unaudited management information, does not include the Company's peak trading period, and is not a forecast of FY27 earnings.

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. All dollar values are in Australian dollars (A$), unless otherwise stated.